Oxford UK, July 16th, 2026. Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic immunotherapies, announces that it has relocated to new, state-of-the-art facilities at ARC Oxford, a growing science and innovation campus close to Oxford’s world-class research institutes, teaching hospitals and university. The company joins a thriving community of more than 30 science and technology companies at ARC Oxford, further strengthening the campus’ position as a hub for cutting-edge innovation.